Previous 10 | Next 10 |
The following slide deck was published by Catalent, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Catalent, Inc. 2022 Q4 - Results - Earnings Call Presentation
The shares of the contract manufacturer Catalent, Inc. ( NYSE: CTLT ) dropped ~10% in pre-market trading Monday after the company reported a mixed performance with its Q4 financials for fiscal 2022, and its guidance for fiscal 2023 fell short of Street forecasts. D...
Catalent press release ( NYSE: CTLT ): FQ4 Non-GAAP EPS of $1.19 beats by $0.04 . Revenue of $1.31B (+10.1% Y/Y) misses by $20M . FY2023 Outlook : Net revenue: $4.975B to $5.225B vs. consensus of $5.28B; Adjusted EBITDA: $1.31B to $1.39B; Adjusted net incom...
Q4'22 net revenue of $1.31 billion increased 10% as reported, or 15% in constant currency, compared to Q4'21. Organic, constant-currency net revenue grew 10%, compared to Q4'21. Fiscal 2022 net revenue of $4.83 billion increased 21% as reported, or 23% in constant curr...
Dan Loeb's 13F portfolio value decreased from $7.68B to $4.22B this quarter. The number of positions decreased from 75 to 58. Third Point added Colgate-Palmolive, Antero Resources, Walt Disney, and T-Mobile US. They also increased Ovintiv. However, net equity exposure was cut sharply ...
Catalent has built up a solid track record of value creation over the past nearly decade long period. The company has seen excellent operating momentum, despite the pandemic being on its retreat. With shares lagging, valuations have become a lot more compelling, not to be confused...
Catalent ( NYSE: CTLT ) to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475M from Mayne Pharma Group Limited. The move will strengthen Catalent's cap...
Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contrac...
Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the fourth qua...
The expansion of primary packaging capabilities in Japan is expected to drive significant growth for Catalent in coming years. Recently, Catalent announced a new operating structure in which the company has consolidated the four segments into two: Biologics and Pharmaceuticals & C...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...